CO2024007500A2 - Uso del interferón como adyuvante en vacunas - Google Patents

Uso del interferón como adyuvante en vacunas

Info

Publication number
CO2024007500A2
CO2024007500A2 CONC2024/0007500A CO2024007500A CO2024007500A2 CO 2024007500 A2 CO2024007500 A2 CO 2024007500A2 CO 2024007500 A CO2024007500 A CO 2024007500A CO 2024007500 A2 CO2024007500 A2 CO 2024007500A2
Authority
CO
Colombia
Prior art keywords
vaccines
interferon
adjuvant
fish
disclosed
Prior art date
Application number
CONC2024/0007500A
Other languages
English (en)
Spanish (es)
Inventor
Oyvind Haugland
Marius Andre De Feijter Karlsen
Linda Helena Hauge
Marit Rode
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2024007500A2 publication Critical patent/CO2024007500A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/38011—Tombusviridae
    • C12N2770/38022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2024/0007500A 2021-12-20 2024-06-14 Uso del interferón como adyuvante en vacunas CO2024007500A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291585P 2021-12-20 2021-12-20
PCT/US2022/081916 WO2023122526A1 (en) 2021-12-20 2022-12-19 Use of interferon as an adjuvant in vaccines

Publications (1)

Publication Number Publication Date
CO2024007500A2 true CO2024007500A2 (es) 2024-07-29

Family

ID=85221940

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0007500A CO2024007500A2 (es) 2021-12-20 2024-06-14 Uso del interferón como adyuvante en vacunas

Country Status (12)

Country Link
US (1) US20250057946A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452313A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025501740A (cg-RX-API-DMAC7.html)
CN (1) CN118434443A (cg-RX-API-DMAC7.html)
AU (1) AU2022419971A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243028A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024001831A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007500A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240245A (cg-RX-API-DMAC7.html)
DK (1) DK202470173A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007696A (cg-RX-API-DMAC7.html)
WO (1) WO2023122526A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
DK202370610A1 (en) * 2022-12-13 2024-07-12 Zoetis Services Llc Methods of vaccine administration to salmonids
CN118956807B (zh) * 2024-10-17 2025-01-24 天津赛萌生物技术有限公司 一种组蛋白乙酰基转移酶突变体及其在生物大分子制备中的应用
WO2026162707A1 (en) 2025-01-31 2026-08-06 Intervet International B.V. Piscine myocarditis virus vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
EP2950816B1 (en) 2013-02-04 2019-07-31 Schweitzer Biotech Company Ltd. The use of dna sequences encoding an interferon as vaccine adjuvants
GB201415789D0 (en) 2014-09-05 2014-10-22 Touchlight Genetics Ltd Synthesis of DNA
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
CN116732145A (zh) 2016-08-16 2023-09-12 塔驰莱特Ip有限公司 闭合线性dna的生产
GB201805683D0 (en) 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
GB202002068D0 (en) 2020-02-14 2020-04-01 Touchlight Ip Ltd DNA synthesis yield improvements

Also Published As

Publication number Publication date
DK202470173A1 (en) 2024-07-12
MX2024007696A (es) 2024-07-01
US20250057946A1 (en) 2025-02-20
CN118434443A (zh) 2024-08-02
CL2024001831A1 (es) 2024-10-18
AU2022419971A1 (en) 2024-07-04
EP4452313A1 (en) 2024-10-30
JP2025501740A (ja) 2025-01-23
CR20240245A (es) 2024-09-13
CL2026000707A1 (es) 2026-04-17
CA3243028A1 (en) 2025-04-07
WO2023122526A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
CL2024001831A1 (es) Uso del interferón como adyuvante en vacunas
MX2018014573A (es) Vacuna contra el virus del zika.
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
UY38889A (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15r¿ y su uso
AR112969A1 (es) Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
AR105470A1 (es) Métodos para inducir una respuesta inmune
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2018007198A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
CL2019002641A1 (es) Composiciones y métodos que involucran moléculas probióticas.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
MX2023012390A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
BR112021017774A2 (pt) Dose baixa de citocina coadministrada com irgd para tratar câncer
CO2021009379A2 (es) Formulaciones y métodos de la vacuna contra el norovirus
BR112023021812A2 (pt) Composição vacinal adjuvantada e métodos
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
CL2018002123A1 (es) Virus de vacuna del síndrome respiratorio y reproductivo porcino
MX2021010348A (es) Composiciones de lawsonia intracellularis y metodos de uso de las mismas.
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
EA202100145A1 (ru) Применение гуанабенза